NCT02975882: Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

NCT02975882
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Chemotherapy, Serine Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients over 21 years of age; Patients who have received prior therapy with ABI-009; Patients who have previously received irinotecan & temozolomide in combination & had significant toxicity; Patients who have received prior therapy with all 3 agents in combination (i.e. irinotecan, temozolomide, & an mTOR inhibitor)
https://ClinicalTrials.gov/show/NCT02975882

Comments are closed.

Up ↑